Combined cytoreductive laser therapy and immunotherapy for palliation of metastatic renal cell carcinoma to the head and neck.
Interleukin-2 (IL-2) remains the mainstay of treatment for metastatic renal cell carcinoma (RCC), but minimally invasive surgical techniques have provided new options for the combined treatment of RCC. Two patients with metastatic RCC to the head and neck treated by combined laser-induced thermal therapy and IL-2 were described in this case report. Both patients had an extended survival compared to the historical survival of 10 months for metastatic RCC but eventually succumbed to progressive disease. The authors' initial experience with metastatic RCC suggests that laser thermoablation and immunotherapy in selected patients with metastatic RCC is warranted as a palliative treatment, but a larger study with long-term follow-up is necessary to determine the effectiveness of this approach.
Paiva
M B
MB
Division of Head and Neck Surgery, Department of Surgery, David Geffen School of Medicine-UCLA, 10833 Le Conte Avenue, CHS62-132, P.O. Box 162418, Los Angeles, CA 90095-1624, USA. mpaiva@mednet.ucla.edu
Sercarz
J A
JA
Pantuck
A J
AJ
Polyakov
M
M
Figlin
R A
RA
Canalis
R F
RF
Castro
D J
DJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology*; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods*
D000970:Antineoplastic Agents; D007376:Interleukin-2